ReviewJugan geon-gang gwa jilbyeong2024
[Global Measles Outbreaks].
Review in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lessons for Immunisation Policy and Practice From the Deadly Measles Resurgence in Bangladesh.Tropical medicine & international health : TM & IH · 2026Article
- Measles challenges: global resurgence and factors affecting eradication.Italian journal of pediatrics · 2026Review
- Incidence and Epidemiologic Characteristics of Measles in the Republic of Korea Following Elimination Verification (2014-2025).Public health weekly report · 2026Article
- Impact of measles vaccination on clinical characteristics and outcomes in children in Ramadi, Iraq.World journal of clinical pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2023, as public health and social measures due to coronavirus disease 2019 (COVID-19) eased and overseas travel resumed, measles cases increased rapidly worldwide. According to the World Health Organization (WHO), approximately 320,000 measles cases were reported worldwide in 2023, 1.8 times higher than approximately 170,000 cases in 2022. Even in countries verified as measles-eradication countries, community epidemics have been observed mainly among unvaccinated and incompletely vaccinated people. The WHO indicated that low vaccination rates and increased international travel are the main causes of the rapid increase in measles outbreaks. During the COVID-19 pandemic, vaccination services were suspended or delayed in many countries, significantly decreasing vaccination rates. Simultaneously, as travel restrictions eased, population movement increased worldwide, creating an environment that made it easy for the measles virus to spread to various regions. The WHO has set the goal of eradicating measles by 2030, and important strategies include maintaining and strengthening vaccination rates, strengthening quarantine, patient surveillance, public health education, and information sharing through international cooperation. As of 2022, the Republic of Korea has maintained a relatively high vaccination rate by meeting the standards for maintaining herd immunity of over 95% recommended by the WHO, with a secondary vaccination rate of 95%. However, there is a risk of transmission through certain age groups and overseas inflows where vaccination rates are relatively low. Therefore, in areas with an active measles outbreak, it is essential to be vaccinated before traveling to areas where outbreaks are increasing, and careful monitoring is necessary to prevent domestic inflow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.